ARS Pharmaceuticals (SPRY) Research & Development (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Research & Development data on file, last reported at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 46.88% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $14.6 million (down 15.8% YoY), and the FY2025 full-year result was $13.2 million, down 32.68% from the prior year.
• Research & Development climbed to $4.3 million in Q1 2026, from $3.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $7.3 million in Q2 2023 to a low of $2.8 million in Q3 2025.
• A 5-year average of $4.5 million and a median of $4.3 million in 2026 frame the typical range for Research & Development.
• Peak annual rise in Research & Development reached 118.57% in 2022, while the deepest fall reached 75.49% in 2022.
• Tracing SPRY's Research & Development over 5 years: stood at $4.7 million in 2022, then declined by 27.73% to $3.4 million in 2023, then dropped by 11.08% to $3.0 million in 2024, then grew by 13.74% to $3.4 million in 2025, then advanced by 25.94% to $4.3 million in 2026.
• Business Quant data shows SPRY's Research & Development at $4.3 million in Q1 2026, $3.4 million in Q4 2025, and $2.8 million in Q3 2025.